Published June 13, 2023
| Version v1
Patent
Open
Car T-cells recognizing cancer-specific IL 13Ra2
Creators
- 1. University of Chicago
- 2. Baylor College of Medicine
Contributors
Patent applicants:
Description
Provided are specific binding molecules, or fragments thereof, that bind to an epitope of IL13Rα2, a receptor polypeptide preferentially found on the surface of cancer cells rather than healthy cells. Exemplary specific binding molecules are bispecific binding molecules that comprise a fragment of an IL13Rα2 binding molecule and a peptide providing a second function providing a signaling function of the signaling domain of a T cell signaling protein, a peptide modulator of T cell activation, or an enzymatic component of a labeling system. Also provided are polynucleotides encoding such a specific binding molecule (e.g., bispecific binding molecule), vectors, host cells, pharmaceutical compositions and methods of preventing, treating or ameliorating a symptom associated with a cancer disease such as a solid tumor disease (e.g., glioblastoma multiforme).
Files
US11673934.pdf
Files
(14.1 MB)
| Name | Size | Download all |
|---|---|---|
|
md5:9d5bbdf6c033123bd30c4b4ef78b64e8
|
14.1 MB | Preview Download |
Additional details
Identifiers
- Patent number
- US 11673935 B2
- Patent application number
- US 201916675861 A
- Other
- oai:uchicago.tind.io:7766
Dates
- Patent filed
-
2019-11-06